Effectiveness of mesoglycan in patients with previous deep venous thrombosis and chronic venous insufficiency.

摘要: AIM Retrospective analysis of mesoglycan therapeutic activity in venous disorders. The clinical data have been selected from the outpatient database Chair Angiology University Catania (from 1988 to 1997) through a cross survey between prescription commercial name and key words varicose veins, deep thrombosis (DVT), chronic insufficiency (CVI), post-thrombotic syndrome (PTS), thrombosis, ulcer. METHODS Patients on basis definite relative principal diagnosis, history, instrumental objective phlebological picture, posology duration treatment, follow-up visits first three years following observation. Group 1: 56 patients with episode DVT; 2: 27 recurrent 3: 182 CVI (107 primitive 75 secondary CVI). included new databases. DVT were evaluated for recurrence prevalence during period (6, 12, 18, 24, 30 36 months). In 2 normal was and, addition, chronology previous observation drawn, order find out thrombotic preceding our two trends ( treatment observation) compared Student t test. (Group 3) classified according CEAP classification criteria. effectiveness assessed changes scores dysfunction (disability score; pain; oedema; skin color change; cutaneous ulcer). mean standard deviation considered test comparing each series immediately T0 series. dose 50 mg twice per day. RESULTS 1 (1(st) DVT): 3.5% at 6 months, 9% 12 12.5% 18 14.28% months. At end 3 PTS diagnosis could be performed 10 (17.85%). (recurrent 3.7% 11.11% 14.81% 24 18.51% months treatment. episode, 16.66% 33.33% 37.03% remaining 62.96% occurred 48 comparison showed significant difference P < 0.0004. 17.85% 81.41% DVT. (CVI): all improvement period, both beginning control visit. CONCLUSION results obtained groups show that is effective preventing 1(st) lower than reported by literature (17.5% within 24.6% 5 years). positive trend also confirmed group, although major (18.51%) due higher risk. However, significantly episode. Mesoglycan patients, progressive disability, pain edema, which are pathophysiologic elements responsible impairment quality life. various points score value reduced values control. conclusion useful medication disorders, subacute phase long-term therapy CVI, worth more extensive documentation, accordance criteria evidence-based medicine.